Latest Insider Transactions at Arcutis Biotherapeutics, Inc. (ARQT)
This section provides a real-time view of insider transactions for Arcutis Biotherapeutics, Inc. (ARQT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcutis Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcutis Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Patrick Burnett Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+25.67%
|
-
|
|
Mar 02
2023
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
1,751
-2.11%
|
$28,016
$16.17 P/Share
|
|
Mar 02
2023
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+34.94%
|
-
|
|
Mar 02
2023
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,434
-3.67%
|
$22,944
$16.17 P/Share
|
|
Mar 02
2023
|
Kenneth A. Lock Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,432
-1.6%
|
$22,912
$16.17 P/Share
|
|
Mar 02
2023
|
Scott L Burrows Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,434
-1.8%
|
$22,944
$16.17 P/Share
|
|
Mar 02
2023
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
5,472
-0.73%
|
$87,552
$16.17 P/Share
|
|
Mar 02
2023
|
Patricia A. Turney SVP, Operations |
SELL
Open market or private sale
|
Direct |
1,432
-1.52%
|
$22,912
$16.17 P/Share
|
|
Mar 02
2023
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,213
-0.24%
|
$19,408
$16.17 P/Share
|
|
Feb 28
2023
|
Kenneth A. Lock Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
936
-2.05%
|
$14,976
$16.17 P/Share
|
|
Feb 28
2023
|
Scott L Burrows Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
416
-1.03%
|
$6,656
$16.17 P/Share
|
|
Feb 28
2023
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
2,343
-0.62%
|
$37,488
$16.17 P/Share
|
|
Feb 28
2023
|
Patricia A. Turney SVP, Operations |
SELL
Open market or private sale
|
Direct |
936
-1.95%
|
$14,976
$16.17 P/Share
|
|
Feb 28
2023
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
792
-0.31%
|
$12,672
$16.17 P/Share
|
|
Feb 15
2023
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
8,500
-4.88%
|
$136,000
$16.98 P/Share
|
|
Feb 15
2023
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+4.65%
|
$8,500
$1.68 P/Share
|
|
Feb 14
2023
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
517
-0.07%
|
$8,789
$17.03 P/Share
|
|
Feb 13
2023
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
483
-0.06%
|
$8,211
$17.01 P/Share
|
|
Feb 01
2023
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.13%
|
$17,000
$17.0 P/Share
|
|
Jan 17
2023
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
8,500
-4.88%
|
$110,500
$13.72 P/Share
|
|
Jan 17
2023
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+4.65%
|
$8,500
$1.68 P/Share
|
|
Jan 03
2023
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
1,475
-3.43%
|
$22,125
$15.01 P/Share
|
|
Dec 07
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.26%
|
$17,000
$17.06 P/Share
|
|
Nov 21
2022
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,720
-8.09%
|
$30,960
$18.19 P/Share
|
|
Nov 18
2022
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+18.66%
|
-
|
|
Nov 15
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
3,403
-2.01%
|
$68,060
$20.01 P/Share
|
|
Nov 15
2022
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,020
+0.6%
|
$1,020
$1.68 P/Share
|
|
Nov 07
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.26%
|
$18,000
$18.0 P/Share
|
|
Oct 07
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.26%
|
$19,000
$19.51 P/Share
|
|
Oct 04
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
6,000
-3.44%
|
$120,000
$20.29 P/Share
|
|
Sep 16
2022
|
Scott L Burrows Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.05%
|
$5,000
$1.68 P/Share
|
|
Sep 07
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.26%
|
$21,000
$21.51 P/Share
|
|
Aug 15
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
6,000
-3.33%
|
$144,000
$24.8 P/Share
|
|
Aug 05
2022
|
Frazier Life Sciences Viii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+2.8%
|
$5,000,000
$20.0 P/Share
|
|
Aug 05
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.38%
|
$60,000
$24.74 P/Share
|
|
Aug 05
2022
|
Todd Franklin Watanabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.38%
|
$2,500
$1.68 P/Share
|
|
Jul 18
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
6,000
-3.22%
|
$144,000
$24.4 P/Share
|
|
Jul 08
2022
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,197
-0.85%
|
$54,925
$25.41 P/Share
|
|
Jul 08
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
13,500
-0.68%
|
$337,500
$25.27 P/Share
|
|
Jul 08
2022
|
Todd Franklin Watanabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,087
+1.06%
|
$7,087
$1.68 P/Share
|
|
Jul 06
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.15%
|
$22,000
$22.07 P/Share
|
|
Jun 24
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
341,971
-7.97%
|
$7,181,391
$21.31 P/Share
|
|
Jun 23
2022
|
Todd Franklin Watanabe Director |
SELL
Bona fide gift
|
Direct |
268,964
-41.26%
|
-
|
|
Jun 06
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.15%
|
$21,000
$21.06 P/Share
|
|
Jun 02
2022
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,795
-9.88%
|
$34,105
$19.73 P/Share
|
|
Jun 01
2022
|
Joseph L Turner Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Keith R Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Patrick J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Sue Jean Lin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+48.32%
|
-
|
|
Jun 01
2022
|
Howard G. Welgus Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+2.26%
|
-
|